Circassia Pharmaceuticals (CIR) Stock Rating Reaffirmed by Peel Hunt
Circassia Pharmaceuticals (LON:CIR)‘s stock had its “buy” rating reiterated by stock analysts at Peel Hunt in a research note issued on Thursday.
Several other research analysts have also commented on the stock. Royal Bank of Canada dropped their price target on shares of Circassia Pharmaceuticals from GBX 86 ($1.12) to GBX 81 ($1.06) and set a “sector performer” rating on the stock in a research note on Wednesday, October 17th. Numis Securities restated a “buy” rating and set a GBX 140 ($1.83) price target on shares of Circassia Pharmaceuticals in a research note on Thursday, September 27th.
Circassia Pharmaceuticals stock opened at GBX 63.50 ($0.83) on Thursday.
Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally.
Featured Article: What is the Ex-Dividend Date in Investing?
Receive News & Ratings for Circassia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.